Tildren Injection

Tiludronic Acid 50 mg/vial
(as disodium tiludronate 56.91 mg/vial)
Powder and solvent for intravenous injection: solvent is water for injection

TILDREN is used to:

• inhibit loss of bone and bone resorption
• protect cartilage

Tiludronic acid belongs to the bisphosphonate therapeutic class, a class of products with activity on bone metabolism. The main pharmacological property of TILDREN injection is to reduce bone resorption by inhibiting the activity of osteoclasts.

TILDREN injection acts as a regulator of bone remodelling in all situations involving excessive bone resorption. This regulator effect is not associated with a negative effect on bone formation or bone mineralisation when used at the recommended therapeutic dosage.

Areas of reduced bone density are a pathological change common to most cases of Navicular Disease and Bone Spavin and are due to inappropriate resorption of bone (“osteolysis”). In double-blind, placebo-controlled clinical trials for both conditions, TILDREN treatment produced clear improvement as demonstrated by long-term reduction in lameness and progressive resumption of sporting activity.1,2

In clinical trials into the treatment of back pain associated with bony lesions of the vertebral column, TILDREN treatment induced an improvement in back flexibility 3. Other studies have shown that TILDREN treatment can prevent the bone loss which usually occurs during inactivity in horses 4. TILDREN has also demonstrated anti-arthritic properties. In vitro data identified inhibiting effects on the secretion of enzymes which degrade cartilage matrix.5

REFERENCES

1. Denoix JM, et al. 2003 Equine Vet. J. 35:407-13.
2. Gough M, et al. 2010 Equine Vet. J. 42: 381-387.
3. Coudry V, et al. 2007 Am. J. Vet. Res. 68:329-337.
4. Delguste C, et al. 2007 Bone 41;414-421.
5. Strassle BW, et al. 2010 Osteoarthr. Cartilage. 18: 1319-1328.

Treatment of lameness associated with bone changes such as those observed in Navicular Disease and Bone Spavin.

Horses:

• 0.1 mg Tiludronic acid per kg bodyweight once daily for 10 days by slow intravenous (IV) injection
• i.e. 10mL (1 vial) of reconstituted solution per 500 kg bodyweight per day for 10 days.
• TILDREN can be administered as a single intravenous infusion diluted into a 1-L infusion bag of 0.9% Sodium Chloride or 5% Glucose solution.
• The product should be infused over 30 minutes.

Administer through a suitable needle or catheter inserted into the jugular vein and connected to the infusion container with sterile disposable infusion tubing, over a 30 minute (minimum) duration.

Where TILDREN is used as part of a treatment regime for Navicular Disease or Bone Spavin, it is important to combine with corrective shoeing.

Users must adhere to local and racing regulations.

WARNINGS: Always consult label and leaflet for restraints, contraindications, precautions and side effects.